J.P. Morgan analyst Jessica Fye maintained a Buy rating on Legend Biotech today and set a price target of $76.00. The company’s shares opened today at $32.05.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Fye is a 5-star analyst with an average return of 10.2% and a 56.41% success rate. Fye covers the Healthcare sector, focusing on stocks such as Insmed, Ascendis Pharma, and Ionis Pharmaceuticals.
In addition to J.P. Morgan, Legend Biotech also received a Buy from RBC Capital’s Leonid Timashev in a report issued yesterday. However, on September 25, BMO Capital assigned a Hold rating to Legend Biotech (NASDAQ: LEGN).
The company has a one-year high of $51.77 and a one-year low of $27.34. Currently, Legend Biotech has an average volume of 1.19M.
Read More on LEGN:
Disclaimer & DisclosureReport an Issue
- Legend Biotech and Janssen Forge Strategic Supply Agreement
- Legend Biotech’s Strategic Positioning and Growth Potential: Overcoming Supply Constraints and Sustaining Leadership in the BCMA CAR T Space
- Legend Biotech in talks for listing outside U.S., Bloomberg says
- Legend Biotech assumed with an Overweight at Cantor Fitzgerald
- Legend Biotech price target raised to $78 from $77 at JPMorgan
/Advanced%20Micro%20Devices%20Inc_%20office%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)